AGEN

Agenus Inc

Oct 17 • 01:13PM ET

3.88

-0.11 -2.76 %

Healthcare • Biotechnology • USA • NASD

Peers: BMY MRK PFE GILD JNJ AMGN VRTX REGN BIIB LLY

| Held by: VTI VXF VHT IWC MSSM BTEC CHNA

Index	-	P/E	-	EPS (ttm)	-7.15	Insider Own	7.00%	Shs Outstand	30.00M	Perf Week	-2.27%
Market Cap	123.63M	Forward P/E	-	EPS next Y	-1.41	Insider Trans	0.00%	Shs Float	29.63M	Perf Month	-14.73%
Enterprise Value	535.15M	PEG	-	EPS next Q	2.20	Inst Own	24.77%	Short Float	7.47%	Perf Quarter	-36.29%
Income	-165.68M	P/S	1.22	EPS this Y	111.14%	Inst Trans	1.57%	Short Ratio	4.16	Perf Half Y	86.54%
Sales	101.71M	P/B	-	EPS next Y	-219.77%	ROA	-69.29%	Short Interest	2.21M	Perf YTD	41.61%
Book/sh	-11.82	P/C	12.97	EPS next 5Y	38.20%	ROE	-	52W High	7.34 -47.14%	Perf Year	-16.74%
Cash/sh	0.30	P/FCF	-	EPS past 3/5Y	-71.25% 7.90%	ROIC	-	52W Low	1.38 181.16%	Perf 3Y	-92.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-29.53% -7.17%	Gross Margin	86.61%	Volatility	5.16% 5.70%	Perf 5Y	-95.46%
Dividend TTM	-	EV/Sales	5.26	EPS Y/Y TTM	36.16%	Oper. Margin	-89.91%	ATR (14)	0.24	Perf 10Y	-95.89%
Dividend Ex-Date	-	Quick Ratio	0.06	Sales Y/Y TTM	-36.29%	Profit Margin	-162.90%	RSI (14)	39.68	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	0.06	EPS Q/Q	60.51%	SMA20	-4.94%	Beta	1.42	Target Price	12.33
Payout	-	Debt/Eq	-	Sales Q/Q	9.28%	SMA50	-10.48%	Rel Volume	1.19	Prev Close	3.99
Employees	316	LT Debt/Eq	-	Earnings	Aug 11 BMO	SMA200	1.67%	Avg Volume	531.67K	Price	3.88
IPO	Feb 04, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	-141.32% -48.30%	Trades		Volume	374,972	Change	-2.76%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-04-25	Upgrade	H.C. Wainwright	Neutral → Buy	$25
Jul-19-24	Downgrade	Robert W. Baird	Outperform → Neutral	$35 → $8
Jul-18-24	Downgrade	William Blair	Outperform → Mkt Perform
Jul-18-24	Downgrade	H.C. Wainwright	Buy → Neutral	$9
Jun-06-23	Initiated	Robert W. Baird	Outperform	$8
Jun-06-23	Initiated	Robert W. Baird	Outperform	$60 → $80
Feb-28-23	Resumed	H.C. Wainwright	Buy	$8
Sep-28-22	Initiated	SMBC Nikko	Outperform	$5
Dec-16-21	Initiated	H.C. Wainwright	Buy	$12
Nov-19-19	Resumed	B. Riley FBR	Buy	$6
Apr-22-19	Initiated	B. Riley FBR	Buy
Oct-28-16	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $5
Oct-27-16	Reiterated	Maxim Group	Buy
Mar-11-16	Upgrade	Maxim Group	Hold → Buy	$7
Dec-16-15	Initiated	Jefferies	Buy
Oct-27-15	Downgrade	Maxim Group	Buy → Hold
Jul-27-15	Reiterated	MLV & Co	Buy	$9 → $11
Jun-11-15	Initiated	Oppenheimer	Outperform	$14
Jan-12-15	Reiterated	Maxim Group	Buy	$10 → $11
Jan-09-15	Reiterated	MLV & Co	Buy	$6 → $9

Show Previous Ratings

Today 08:00AM	Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025 (Business Wire)
Oct-16-25 07:48AM	Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights (Business Wire)
Sep-23-25 10:14AM	Are Options Traders Betting on a Big Move in Agenus tock? (Zacks)
Sep-09-25 07:43AM	France Grants Reimbursed Compassionate Access (AAC) for Agenus BOT/BAL in Refractory MSS Metastatic Colorectal Cancer (Business Wire) +19.01%
Sep-05-25 08:52AM	Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
10:44AM	Loading…
Aug-28-25 10:44AM	FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone (PR Newswire) -6.39%
Aug-26-25 09:37AM	Update: Agenus Aug 27 Stakeholder Webcast-Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight (Business Wire) +5.47%
09:19AM	What To Expect From Agenus Inc (AGEN) Q2 2025 Earnings (GuruFocus.com)
Aug-19-25 07:30AM	Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025 (Business Wire)
Aug-11-25 06:55PM	Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -11.04% +12.65%
06:06PM	Agenus: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress (Business Wire)
Aug-07-25 05:40PM	Gilead Sciences (GILD) Tops Q2 Earnings and Revenue Estimates (Zacks)
Aug-06-25 05:25PM	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -10.02%
Aug-01-25 09:05AM	Zacks.com featured highlights include QuantumScape, Civeo and Agenus (Zacks)
03:00PM	Loading…
Jul-31-25 03:00PM	QuantumScape & 2 Other Stocks to Buy for Earnings Acceleration (Zacks) -6.44%
07:30AM	Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report (Business Wire)
Jul-30-25 09:40AM	Is CVS Health (CVS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-29-25 03:46PM	Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments (PR Newswire) -7.40%
Jul-25-25 12:46PM	Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025 (Business Wire)
Jul-24-25 10:45AM	VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales (Zacks)
Jul-22-25 09:15AM	From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits (PR Newswire)
Jul-17-25 01:07PM	AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies (Zacks) +5.66%
11:34AM	MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights (Zacks)
07:00AM	US FDA Approves GSKs SHINGRIX in a Prefilled Syringe Presentation (Business Wire)
Jul-15-25 08:32AM	AstraZeneca Meets All Key Goals in Phase III Hypertension Study (Zacks) -8.93%
08:28AM	Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA (Zacks)
Jul-14-25 09:40AM	Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:39AM	Agenus (AGEN) Surges 19.3%: Is This an Indication of Further Gains? (Zacks)
Jul-11-25 07:30AM	MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer (GlobeNewswire) +19.26%
09:11AM	Loading…
Jul-10-25 09:11AM	KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? (Zacks) +14.29%
04:42AM	Zacks.com featured highlights Yext, Agenus and NCR Voyix (Zacks)
Jul-09-25 12:26PM	PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study (Zacks) +6.58%
Jul-08-25 03:00PM	3 Top Earnings Acceleration Stocks to Buy for 2H25 (Zacks) -6.18%
Jul-07-25 08:55AM	Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3 (Business Wire) -14.66%
Jul-02-25 10:32AM	Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli (Zacks) +13.84%
Jul-01-25 10:50AM	Biogen Begins Phase III Felzartamab Study for Third Kidney Disease (Zacks) +5.91%
09:17AM	Moderna Stock Gains on Encouraging Flu Vaccine Data (Zacks)
Jun-30-25 11:40AM	RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome (Zacks)
Jun-27-25 09:40AM	Are Medical Stocks Lagging CVS Health (CVS) This Year? (Zacks)
Jun-25-25 11:17AM	KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study (Zacks)
11:06AM	Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU (Zacks)
10:02AM	Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag (Zacks)
Jun-24-25 11:58AM	CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication (Zacks)
09:04AM	FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer (Zacks)
Jun-23-25 09:15AM	J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications (Zacks)
Jun-19-25 09:55AM	After Golden Cross, Agenus (AGEN)'s Technical Outlook is Bright (Zacks)
Jun-17-25 12:02PM	Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy (Zacks) -7.00%
10:30AM	AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study (Zacks)
07:30AM	Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology (Business Wire)
Jun-16-25 03:01PM	Agenus Inc. (AGEN) Surges After Zydus Agreement, Analysts Upbeat on Stock (Insider Monkey) +9.36%
08:45AM	SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion (Zacks)
Jun-10-25 01:30PM	Agenus Announces Virtual Annual Shareholders Meeting (Business Wire)
Jun-05-25 10:03AM	FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector (Zacks) -8.35%
Jun-04-25 09:55AM	Wall Street Analysts Believe Agenus (AGEN) Could Rally 26.6%: Here's is How to Trade (Zacks) +12.60%
07:33AM	Agenus and Zydus sign agreements for botensilimab and balstilimab (Pharmaceutical Technology)
Jun-03-25 07:00AM	Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus Biologics Manufacturing in the US (Business Wire) +21.07%
May-30-25 07:30AM	Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer (Business Wire) +7.19%
May-29-25 11:18AM	SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal (Zacks) +5.96%
11:08AM	U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot (Zacks)
May-19-25 09:06AM	BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz (Zacks) +8.91%
08:50AM	Despite Fast-paced Momentum, Agenus (AGEN) Is Still a Bargain Stock (Zacks)
May-16-25 10:45AM	Agenus says expanded MSS mCRC cohort data to be presented at ESMO GI (TipRanks)
May-15-25 10:40AM	Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025 (Business Wire)
08:42AM	AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer (Zacks)
May-14-25 06:29AM	Allogene's Q1 Earnings In Line With Estimates, Sales Nil (Zacks)
May-13-25 03:03AM	Agenus Inc (AGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges (GuruFocus.com)
02:57AM	Q1 2025 Agenus Inc Earnings Call (Thomson Reuters StreetEvents)
May-12-25 08:50AM	Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +20.27%
07:47AM	Agenus: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Agenus Reports Q1 2025 Financial Results and Key Business Updates (Business Wire)
07:20AM	Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer (Business Wire)
May-09-25 09:47AM	Agenus Inc (AGEN) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
09:40AM	Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? (Zacks)
May-08-25 09:25AM	MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates (Zacks)
May-07-25 06:15PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
12:42PM	Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y (Zacks)
May-05-25 05:15PM	Vertex Pharmaceuticals (VRTX) Misses Q1 Earnings and Revenue Estimates (Zacks)
Apr-29-25 10:01AM	Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
07:30AM	Agenus to Provide Corporate Update and First Quarter 2025 Financial Report (Business Wire)
Apr-28-25 03:30PM	Agenus BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR (Business Wire) +16.30%
Apr-25-25 01:05PM	Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025 (Business Wire)
Apr-23-25 12:05PM	Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025 (Business Wire)
09:40AM	Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? (Zacks)
Apr-10-25 08:52AM	Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus (Zacks) -6.09%
Mar-25-25 04:40PM	Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025 (Business Wire)
09:55AM	Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Mar-19-25 07:30AM	Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation (Business Wire)
Mar-12-25 03:03AM	Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges (GuruFocus.com) -9.02%
01:35AM	Q4 2024 Agenus Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-11-25 11:45AM	Agenus (AGEN) Q4 2024 Earnings Call Transcript (Motley Fool)
08:40AM	Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:43AM	Agenus: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program (Business Wire)
Feb-26-25 04:48PM	Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications (Business Wire) -8.63%
Feb-25-25 02:30PM	Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference (Business Wire)
08:26AM	Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report (Business Wire)
Feb-24-25 08:33AM	Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting (Business Wire)
Feb-23-25 07:38PM	CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting (Business Wire)
Feb-21-25 09:40AM	Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? (Zacks)

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Agenus Inc.	Owner	Aug 29 '25	Proposed Sale	15.98	786,750	12,572,265		Aug 29 05:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AGEN

Agenus Inc

Upgrade your FINVIZ experience